CNTA
Centessa Pharmaceuticals plc NASDAQ Listed May 28, 2021$39.62
Mkt Cap $5.9B
52w Low $10.95
97.8% of range
52w High $40.26
50d MA $33.72
200d MA $25.52
P/E (TTM)
-27.1x
EV/EBITDA
-16.1x
P/B
10.2x
Debt/Equity
0.2x
ROE
-51.4%
P/FCF
-17.5x
RSI (14)
—
ATR (14)
—
Beta
1.26
50d MA
$33.72
200d MA
$25.52
Avg Volume
2.6M
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
3RD FLOOR · ALTRINCHAM, CHESHIRE, X0 WA14 2DT · GB
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -0.37 | -0.48 | -29.2% | 39.72 | +0.1% | +0.4% | -0.4% | -0.1% | -0.3% | -0.1% | — |
| Nov 5, 2025 | AMC | -0.39 | -0.41 | -5.1% | 22.52 | -1.5% | +1.4% | -3.2% | +0.9% | +0.9% | +18.5% | — |
| Aug 12, 2025 | AMC | -0.35 | -0.38 | -8.6% | 17.11 | +0.5% | +0.2% | +2.9% | +2.3% | -2.5% | -1.4% | — |
| May 14, 2025 | AMC | -0.35 | -0.20 | +42.9% | 12.27 | -0.5% | +2.6% | -0.6% | -2.0% | +7.7% | -2.9% | — |
| Mar 24, 2025 | AMC | -0.38 | -0.34 | +10.5% | 16.63 | -0.6% | -4.9% | -8.0% | -0.2% | +0.6% | -1.4% | — |
| Nov 12, 2024 | AMC | -0.42 | -0.37 | +11.9% | 17.00 | +3.4% | +6.4% | -3.2% | -8.6% | +0.6% | +4.5% | — |
| Aug 13, 2024 | AMC | -0.38 | -0.40 | -5.3% | 11.01 | +3.1% | +14.4% | +3.9% | -4.5% | -1.5% | -2.4% | — |
| May 13, 2024 | AMC | -0.41 | -0.38 | +7.3% | 8.83 | -0.2% | +2.4% | -2.8% | +1.8% | -0.9% | -1.7% | — |
| Mar 28, 2024 | AMC | -0.44 | -0.38 | +13.6% | 11.30 | +1.5% | -1.9% | +2.3% | -4.5% | -4.2% | +3.7% | — |
| Nov 13, 2023 | AMC | -0.46 | -0.40 | +13.0% | 6.24 | +3.8% | +6.2% | +8.7% | -3.2% | +0.9% | -2.8% | — |
| Aug 14, 2023 | AMC | -0.43 | -0.26 | +39.5% | 6.62 | +2.0% | +4.4% | -5.1% | -4.7% | +2.2% | +6.6% | — |
| May 12, 2023 | AMC | -0.41 | -0.53 | -29.3% | 4.65 | +0.6% | -0.2% | -3.7% | +4.5% | -5.8% | +4.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $39.66 | $39.60 | -0.2% | -0.4% | -0.1% | -0.1% | -0.1% | +0.1% |
| Apr 2 | Guggenheim | Downgrade | Buy → Neutral | — | $39.86 | $39.70 | -0.4% | -0.4% | -0.1% | -0.3% | -0.1% | +0.6% |
| Apr 1 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $39.72 | $39.75 | +0.1% | +0.4% | -0.4% | -0.1% | -0.3% | -0.1% |
| Mar 31 | Wolfe Research | Downgrade | Outperform → Peer Perform | — | $27.58 | $40.03 | +45.1% | +44.0% | +0.4% | -0.4% | -0.1% | -0.3% |
| Mar 31 | Needham | Downgrade | Buy → Hold | — | $27.58 | $40.03 | +45.1% | +44.0% | +0.4% | -0.4% | -0.1% | -0.3% |
| Jan 29 | Truist | Maintains | Buy → Buy | — | $25.24 | $25.39 | +0.6% | -1.4% | -1.3% | +2.5% | +1.2% | -1.9% |
| Jan 8 | Truist | Maintains | Buy → Buy | — | $22.69 | $22.75 | +0.3% | -2.8% | +1.7% | -1.8% | +0.9% | -0.6% |
| Jan 2 | Chardan Capital | Maintains | Buy → Buy | — | $25.01 | $24.88 | -0.5% | -5.3% | -2.8% | -1.5% | +0.0% | -2.8% |
| Dec 10 | Oppenheimer | Maintains | Outperform → Outperform | — | $28.60 | $29.11 | +1.8% | +3.4% | -8.1% | -2.5% | -1.4% | -1.6% |
| Dec 1 | B. Riley Securities | Maintains | Buy → Buy | — | $29.03 | $29.63 | +2.1% | -1.9% | +0.1% | +2.0% | +1.7% | +1.2% |
| Nov 18 | Guggenheim | Maintains | Buy → Buy | — | $27.32 | $27.44 | +0.4% | +3.8% | -1.3% | -1.6% | +1.6% | +5.0% |
| Nov 13 | Wells Fargo | Maintains | Overweight → Overweight | — | $26.70 | $26.20 | -1.9% | -2.7% | +6.3% | -1.1% | +3.8% | -1.3% |
| Nov 7 | Wells Fargo | Maintains | Overweight → Overweight | — | $22.84 | $22.44 | -1.8% | -3.2% | +0.9% | +0.9% | +18.5% | -2.7% |
| Oct 6 | Guggenheim | Maintains | Buy → Buy | — | $23.23 | $23.65 | +1.8% | -1.0% | +0.5% | -3.5% | +2.4% | -2.3% |
| Aug 12 | Chardan Capital | Maintains | Buy → Buy | — | $16.61 | $16.30 | -1.9% | +3.0% | +0.2% | +2.9% | +2.3% | -2.5% |
| Jul 30 | Chardan Capital | Maintains | Buy → Buy | — | $15.21 | $15.25 | +0.3% | +8.9% | +3.7% | -2.1% | -4.3% | +7.6% |
| Mar 26 | Guggenheim | Maintains | Buy → Buy | — | $15.81 | $15.40 | -2.6% | -8.0% | -0.2% | +0.6% | -1.4% | -8.0% |
| Feb 10 | Guggenheim | Maintains | Buy → Buy | — | $19.03 | $18.99 | -0.2% | -6.5% | -3.0% | +4.3% | -2.1% | -3.1% |
| Nov 15 | Guggenheim | Maintains | Buy → Buy | — | $17.50 | $17.79 | +1.7% | -8.6% | +0.6% | +4.5% | -0.5% | +8.7% |
| Sep 19 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $15.71 | $16.49 | +5.0% | +0.9% | +4.6% | -6.1% | -0.3% | -1.2% |
| Sep 16 | BMO Capital | Maintains | Outperform → Outperform | — | $16.99 | $17.50 | +3.0% | -3.1% | -1.1% | -3.5% | +0.9% | +4.6% |
| Sep 11 | Guggenheim | Maintains | Buy → Buy | — | $14.58 | $14.79 | +1.4% | -5.7% | +9.8% | +12.5% | -3.1% | -1.1% |
| Sep 11 | Jefferies | Maintains | Buy → Buy | — | $14.58 | $14.79 | +1.4% | -5.7% | +9.8% | +12.5% | -3.1% | -1.1% |
| Sep 9 | BMO Capital | Maintains | Outperform → Outperform | — | $14.30 | $14.72 | +2.9% | +4.4% | -2.3% | -5.7% | +9.8% | +12.5% |
| Aug 14 | Oppenheimer | Maintains | Outperform → Outperform | — | $11.01 | $11.35 | +3.1% | +14.4% | +3.9% | -4.5% | -1.5% | -2.4% |
| Jun 21 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $8.86 | $9.00 | +1.6% | +2.7% | -2.3% | +0.0% | +1.1% | -0.1% |
| Apr 1 | BMO Capital | Maintains | Outperform → Outperform | — | $11.30 | $11.47 | +1.5% | -1.9% | +2.3% | -4.5% | -4.2% | +3.7% |
| Nov 15 | Jefferies | Upgrade | Hold → Buy | — | $6.63 | $7.48 | +12.8% | +8.7% | -3.2% | +0.9% | -2.8% | -4.2% |
| Oct 26 | Morgan Stanley | Upgrade | Underweight → Equal Weight | — | $6.24 | $7.06 | +13.1% | +8.8% | -9.4% | +7.3% | -0.5% | +4.3% |
| Aug 15 | Guggenheim | Maintains | Buy → Buy | — | $6.62 | $6.75 | +2.0% | +4.4% | -5.1% | -4.7% | +2.2% | +6.6% |
| Aug 15 | SVB Securities | Maintains | Outperform → Outperform | — | $6.62 | $6.75 | +2.0% | +4.4% | -5.1% | -4.7% | +2.2% | +6.6% |
| Aug 15 | Goldman Sachs | Maintains | Neutral → Neutral | — | $6.62 | $6.75 | +2.0% | +4.4% | -5.1% | -4.7% | +2.2% | +6.6% |
| Jul 25 | BMO Capital | Maintains | Outperform → Outperform | — | $6.74 | $7.09 | +5.2% | +5.9% | +2.9% | -8.4% | +18.4% | -0.9% |
| May 15 | Goldman Sachs | Maintains | Neutral → Neutral | — | $4.65 | $4.68 | +0.6% | -0.2% | -3.7% | +4.5% | -5.8% | +4.3% |
| Jan 24 | Morgan Stanley | Maintains | Underweight → Underweight | — | $3.87 | $3.83 | -1.0% | +0.0% | -0.8% | +4.2% | -5.5% | +0.8% |
| Aug 12 | Morgan Stanley | Downgrade | Overweight → Underweight | — | $4.28 | $4.17 | -2.6% | -0.5% | -8.7% | +10.0% | -0.9% | +1.9% |
| Aug 11 | Goldman Sachs | Maintains | Neutral → Neutral | — | $4.75 | $4.71 | -0.8% | -9.9% | -0.5% | -8.7% | +10.0% | -0.9% |
| Aug 11 | BMO Capital | Maintains | Outperform → Outperform | — | $4.75 | $4.71 | -0.8% | -9.9% | -0.5% | -8.7% | +10.0% | -0.9% |
| Jul 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $4.98 | $5.02 | +0.8% | +4.6% | -2.9% | -1.2% | +7.2% | -2.8% |
| May 24 | Morgan Stanley | Maintains | Overweight → Overweight | — | $4.49 | $4.39 | -2.2% | -3.3% | -5.1% | +3.6% | -2.1% | +7.7% |
| May 24 | Goldman Sachs | Maintains | Neutral → Neutral | — | $4.49 | $4.39 | -2.2% | -3.3% | -5.1% | +3.6% | -2.1% | +7.7% |
| Apr 5 | Morgan Stanley | Maintains | Overweight → Overweight | — | $9.85 | $9.91 | +0.6% | -2.8% | +1.7% | -2.4% | +1.4% | -1.0% |
No insider trades available.
8-K
Eli Lilly and Company -- 8-K Filing
Eli Lilly's strong Q1 2026 results—revenue up 56% to $19.8B and EPS up 170% to $8.26—combined with raised full-year guidance demonstrate robust momentum despite Mounjaro/Zepbound price pressure, signaling sustained growth.
Apr 30
8-K
Centessa Pharmaceuticals plc -- 8-K Filing
Centessa Pharmaceuticals executed a separation agreement with extended benefits and a general release of claims, effective after a seven-business-day revocation period.
Feb 13
Data updated apr 26, 2026 10:13am
· Source: massive.com